Table I.

Study Design

Groups		Treatment/ genotype		Start of treat- ment		Challenge		Termina- tion of experi- ment
				d				h
Experiment I
1		IgG		−2		SAL ×2		8
2		mAb NK1.1		−2		SAL ×2		8
3		IgG		−2		OVA ×2		8
4		mAb NK1.1		−2		OVA ×2		8
5		IgG		−2		SAL ×7		8
6		mAb NK1.1		−2		SAL ×7		8
7		IgG		−2		OVA ×7		8
8		mAb NK1.1		−2		OVA ×7		8
Experiment II
9		IgG		−2		OVA ×7		8
10		mAb NK1.1		−2		OVA ×7		8
11		mAb NK1.1		−7		OVA ×7		8
12		IgG		13		OVA ×7		8
13		mAb NK1.1		13		OVA ×7		8
14		IgG		−2		OVA ×7		30
15		mAb NK1.1		−2		OVA ×7		30
Experiment III
16		Wild-type  (CD1+/+)		–		OVA ×7		8
17		CD1d1 mutant  (CD1−/−)		–		OVA ×7		8
Experiment IV
18		Wild-type		–		SAL ×7		24
19		Wild-type		–		OVA ×7		24
20		γ/δ T cell–  deficient		–		OVA ×7		24

Four independent experiments were performed and are shown separately. All mice were immunized with OVA on day 0.